LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Factsheet – A long journey to care, or why it’s time for an ambitious EU framework for a cross-border healthcare

07/09/2022
FACTSHEET
#VisionforEurope: Innovation, Investment, Excellence

A long journey to care, or why it’s time for an ambitious EU framework for a cross-border healthcare

Adam is a 76-year-old Polish citizen who suffers from the late-stage Alzheimer and travels once a month to Germany for an advanced treatment. This treatment, which is not available in his country allow him to respond better to the environment, carry on a conversation with his family, and at least partially to control his movement.

He is one of 200,000 patients (0.05% of the EU population) who every year seek healthcare abroad under the framework of the Cross-border Healthcare Directive (Directive 2011/24/EU), principally in a neighbouring Member State to their country of residence. In 2019, 290,890 patients sought healthcare in another Member State.

The Directive aims to guarantee EU patients’ right of access to safe and high-quality healthcare across national borders within the EU/EEA, their rights to be reimbursed for such care, and to facilitate the cross-border exchange of and access to patients’ data.

The Directive’s contributions to improve the treatment of rare disease patients is well recognised. The 24 European Reference Networks (ERNs) have had a positive impact for patients by facilitating the exchange of knowledge and best practices across the EU, although they could be further improved and expended.

In fact, the Directive has delivered a limited positive impact for many patients. Such was the conclusion of the European Court of Auditors in 2019 and of many citizens who received healthcare under the Directive.

Patients are required to deal with a complex system of lengthy administrative procedures to determine whether their treatments are eligible and often have to seek prior authorisation, for which national procedures differ widely. Patients must also bear the upfront cost of their treatment and may not be reimbursed its full cost, excluding many European citizens from the equality of access that Europe strives to achieve in healthcare.

The Directive is an essential tool for Europe to improve patients’ access to specialised treatments such as advanced therapy medicinal products (ATMPs) and orphan medicines for whom cross-border treatment is often the only available solution.

These innovative treatments, based on genes, tissues, or cells, are the next generation of care and build on Europe’s excellence in research and innovation. Unlike many current medicines, they offer the prospect of curing diseases like Alzheimer’s for the first time or effectively treating cancers with single or small number of treatments. Yet, ATMPs require a level of expertise and infrastructure, including manufacturing, processing, and healthcare delivery that is not available in all 27 EU countries, and will never be viable to do so, particularly for rare diseases.

As such, patients often need to seek crossborder care through the Coordination of Social Security Regulations, an equally complex and restrictive system, due to the necessity to request prior authorisation, that does not provide reimbursement for all costs associated with the treatment, such as travel and accommodation further adding to patients’ burdens.

All these administrative complexities added to different national rules and procedures for eligibility of treatments only delay patients access to life-saving treatments and increase the burden on themselves and their families.

As the European Commission finalises its first evaluation of the Cross-Border Healthcare Directive after more than 10 years, it has the opportunity to strive for an ambitious and future-ready Directive. A revision can address shortcomings linked to ease and equality of access, and patient empowerment through a well-functioning and integrated EU cross-border healthcare framework which harnesses Europe’s clinical excellence. Harmonised and simplified administrative procedures, including for payment and reimbursements, expanded and better integrated ERNs, and easier access to cross-border clinical trials are objectives that can be achieved by revising the Directive.

If the European Health Union born out of the COVID-19 pandemic is to succeed, it needs to bring real benefits to citizens across Europe. Guaranteeing simpler and wider access to care, in particular for innovative treatments, is where the EU can excel and bring significant added value from integration and collaboration.

Factsheet - A long journey to care, or why it’s time for an ambitious EU framework for a cross-border healthcare


Download
Cross-border healthcareDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.